VARC-2-defined device success [25] was achieved in 89.5% of patients without diabetes, 89.4% of patients with orally treated diabetes and 88.8% of patients with insulin-treated diabetes (p = 0.944). This evidence concerns the gene INS and diabetes mellitus.